Fluoxetine maintains a state of heightened responsiveness to motor training early after stroke in a mouse model

Stroke

Volumn 46, Issue 10, 2015, Pages 2951-2960

  Ng, Kwan L ^a   Gibson, Ellen M ^a   Hubbard, Robert ^a   Yang, Juemin ^a   Caffo, Brian ^b   O'Brien, Richard J ^c   Krakauer, John W ^a   Zeiler, Steven R ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fluoxetine; motor cortex; Neuronal plasticity; Recovery; Stroke; Upper extremity

Indexed keywords

CALBINDIN; CALRETININ; FLUOXETINE; PARVALBUMIN; SODIUM CHLORIDE; SEROTONIN UPTAKE INHIBITOR;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DEATH; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DENDRITE; FORELIMB; HEART STROKE VOLUME; INTERNEURON; MALE; MOTOR PERFORMANCE; MOUSE; NERVE CELL PLASTICITY; NERVE FIBER; NONHUMAN; PERIKARYON; PREMOTOR CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE FIXATION; ANIMAL; ANIMAL BEHAVIOR; CONVALESCENCE; DISEASE MODEL; DRUG EFFECTS; MOTOR ACTIVITY; MOTOR CORTEX; MOVEMENT (PHYSIOLOGY); NEUROREHABILITATION; PATHOLOGY; PATHOPHYSIOLOGY; STROKE; TIME TO TREATMENT;

ANIMALS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; FLUOXETINE; MALE; MICE; MOTOR ACTIVITY; MOTOR CORTEX; MOTOR SKILLS; MOVEMENT; NEUROLOGICAL REHABILITATION; NEURONAL PLASTICITY; RECOVERY OF FUNCTION; SEROTONIN UPTAKE INHIBITORS; STROKE; TIME-TO-TREATMENT;

EID: 84942893210     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.115.010471     Document Type: Article

References (84)

1. Prabhakaran S, Zarahn E, Riley C, Speizer A, Chong JY, Lazar RM, et al. Inter-individual variability in the capacity for motor recovery after ischemic stroke. Neurorehabil Neural Repair. 2008;22:64-71. doi: 10.1177/1545968307305302.
2. Jørgensen HS, Nakayama H, Raaschou HO, Olsen TS. Stroke. Neurologic and functional recovery the Copenhagen Stroke Study. Phys Med Rehabil Clin N Am. 1999;10:887-906.
3. Hankey GJ, Spiesser J, Hakimi Z, Bego G, Carita P, Gabriel S. Rate, degree, and predictors of recovery from disability following isch-emic stroke. Neurology. 2007;68:1583-1587. doi: 10.1212/01. wnl.0000260967.77422.97.
4. Duncan PW, Goldstein LB, Matchar D, Divine GW, Feussner J. Measurement of motor recovery after stroke. Outcome assessment and sample size requirements. Stroke. 1992;23:1084-1089.
5. Biernaskie J, Chernenko G, Corbett D. Effcacy of rehabilitative experience declines with time after focal ischemic brain injury. J Neurosci. 2004;24:1245-1254. doi: 10.1523/JNEUROSCI.3834-03.2004.
6. Krakauer JW, Carmichael ST, Corbett D, Wittenberg GF. Getting neurore-habilitation right: what can be learned from animal models? Neurorehabil Neural Repair. 2012;26:923-931. doi: 10.1177/1545968312440745.
7. Biernaskie J, Corbett D. Enriched rehabilitative training promotes improved forelimb motor function and enhanced dendritic growth after focal ischemic injury. J Neurosci. 2001;21:5272-5280.
8. Li S, Overman JJ, Katsman D, Kozlov SV, Donnelly CJ, Twiss JL, et al. An age-related sprouting transcriptome provides molecular control of axonal sprouting after stroke. Nat Neurosci. 2010;13:1496-1504. doi: 10.1038/nn.2674.
9. Zeiler SR, Krakauer JW. The interaction between training and plasticity in the poststroke brain. Curr Opin Neurol. 2013;26:609-616. doi: 10.1097/WCO.0000000000000025.
10. Urban ET III, Bury SD, Barbay HS, Guggenmos DJ, Dong Y, Nudo RJ. Gene expression changes of interconnected spared cortical neurons 7 days after ischemic infarct of the primary motor cortex in the rat. Mol Cell Biochem. 2012;369:267-286. doi: 10.1007/s11010-012-1390-z.
11. Clarkson AN, Huang BS, Macisaac SE, Mody I, Carmichael ST. Reducing excessive GABA-mediated tonic inhibition promotes functional recovery after stroke. Nature. 2010;468:305-309. doi: 10.1038/nature09511.
12. Manganotti P, Acler M, Zanette GP, Smania N, Fiaschi A. Motor cortical disinhibition during early and late recovery after stroke. Neurorehabil Neural Repair. 2008;22:396-403. doi: 10.1177/1545968307313505.
13. Clarkson AN, López-Valdés HE, Overman JJ, Charles AC, Brennan KC, Thomas Carmichael S. Multimodal examination of structural and functional remapping in the mouse photothrombotic stroke model. J Cereb Blood Flow Metab. 2013;33:716-723. doi: 10.1038/jcbfm.2013.7.
14. Hinman JD, Rasband MN, Carmichael ST. Remodeling of the axon initial segment after focal cortical and white matter stroke. Stroke. 2013;44:182-189. doi: 10.1161/STROKEAHA.112.668749.
15. Müller HD, Hanumanthiah KM, Diederich K, Schwab S, Schäbitz WR, Sommer C. Brain-derived neurotrophic factor but not forced arm use improves long-term outcome after photothrombotic stroke and transiently upregulates binding densities of excitatory glutamate receptors in the rat brain. Stroke. 2008;39:1012-1021. doi: 10.1161/STROKEAHA.107.495069.
16. Schäbitz WR, Berger C, Kollmar R, Seitz M, Tanay E, Kiessling M, et al. Effect of brain-derived neurotrophic factor treatment and forced arm use on functional motor recovery after small cortical ischemia. Stroke. 2004;35:992-997. doi: 10.1161/01.STR.0000119754.85848.0D.
17. Ploughman M, Windle V, MacLellan CL, White N, Doré JJ, Corbett D. Brain-derived neurotrophic factor contributes to recovery of skilled reaching after focal ischemia in rats. Stroke. 2009;40:1490-1495. doi: 10.1161/STROKEAHA.108.531806.
18. Chollet F, Tardy J, Albucher JF, Thalamas C, Berard E, Lamy C, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol. 2011;10:123-130. doi: 10.1016/S1474-4422(10)70314-8.
19. Acler M, Robol E, Fiaschi A, Manganotti P. A double blind placebo RCT to investigate the effects of serotonergic modulation on brain excitability and motor recovery in stroke patients. J Neurol. 2009;256:1152-1158. doi: 10.1007/s00415-009-5093-7.
20. Mikami K, Jorge RE, Adams HP Jr, Davis PH, Leira EC, Jang M, et al. Effect of antidepressants on the course of disability following stroke. Am J Geriatr Psychiatry. 2011;19:1007-1015. doi: 10.1097/JGP.0b013e31821181b0.
21. Mead GE, Hsieh CF, Lee R, Kutlubaev M, Claxton A, Hankey GJ, et al. Selective serotonin reuptake inhibitors for stroke recovery: a systematic review and meta-analysis. Stroke. 2013;44:844-850. doi: 10.1161/STROKEAHA.112.673947.
22. Maya Vetencourt JF, Sale A, Viegi A, Baroncelli L, De Pasquale R, O'Leary OF, et al. The antidepressant fuoxetine restores plasticity in the adult visual cortex. Science. 2008;320:385-388. doi: 10.1126/science.1150516.
23. Méndez P, Pazienti A, Szabó G, Bacci A. Direct alteration of a specifc inhibitory circuit of the hippocampus by antidepressants. J Neurosci. 2012;32:16616-16628. doi: 10.1523/JNEUROSCI.1720-12.2012.
24. Maya-Vetencourt JF, Tiraboschi E, Greco D, Restani L, Cerri C, Auvinen P, et al. Experience-dependent expression of NPAS4 regulates plasticity in adult visual cortex. J Physiol. 2012;590(pt 19):4777-4787. doi: 10.1113/jphysiol.2012.234237.
25. Zeiler SR, Gibson EM, Hoesch RE, Li MY, Worley PF, O'Brien RJ, et al. Medial premotor cortex shows a reduction in inhibitory markers and mediates recovery in a mouse model of focal stroke. Stroke. 2013;44:483-489. doi: 10.1161/STROKEAHA.112.676940.
26. Farr TD, Whishaw IQ. Quantitative and qualitative impairments in skilled reaching in the mouse (Mus musculus) after a focal motor cortex stroke. Stroke. 2002;33:1869-1875.
27. Paxinos G, Franklin KBJ. Plates. In: The Mouse Brain in Stereotaxic Coordinates. 2nd ed. San Diego, CA: Academic Press; 2001:49-350.
28. Tennant KA, Adkins DL, Donlan NA, Asay AL, Thomas N, Kleim JA, et al. The organization of the forelimb representation of the C57BL/6 mouse motor cortex as defned by intracortical microstimulation and cytoarchitecture. Cereb Cortex. 2011;21:865-876. doi: 10.1093/cercor/bhq159.
29. Ohira K, Takeuchi R, Iwanaga T, Miyakawa T. Chronic fuoxetine treatment reduces parvalbumin expression and perineuronal nets in gamma-aminobutyric acidergic interneurons of the frontal cortex in adult mice. Mol Brain. 2013;6:43. doi: 10.1186/1756-6606-6-43.
30. Das RK, Pal M, Barui A, Paul RR, Chakraborty C, Ray AK, et al. ApoTome to visualize E-cadherin and p63 expression in oral pre-cancer. Biotechnol J. 2012;7:602-607. doi: 10.1002/biot.201100013.
31. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982;38:963-974.
32. Verbeke G, Molenberghs G. Linear mixed models for longitudinal data. Springer series in statistics. New York: Springer Science & Business Media; 2009:1-484.
33. Shin TK, Kang MS, Lee HY, Seo MS, Kim SG, Kim CD, et al. Fluoxetine and sertraline attenuate postischemic brain injury in mice. Korean J Physiol Pharmacol. 2009;13:257-263. doi: 10.4196/kjpp.2009.13.3.257.
34. Lim CM, Kim SW, Park JY, Kim C, Yoon SH, Lee JK. Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-infamma-tory effect. J Neurosci Res. 2009;87:1037-1045. doi: 10.1002/jnr.21899.
35. Zhu BG, Sun Y, Sun ZQ, Yang G, Zhou CH, Zhu RS. Optimal dosages of fuoxetine in the treatment of hypoxic brain injury induced by 3-nitro-propionic acid: implications for the adjunctive treatment of patients after acute ischemic stroke. CNS Neurosci Ther. 2012;18:530-535. doi: 10.1111/j.1755-5949.2012.00315.x.
36. Duckworth EA, Butler TL, De Mesquita D, Collier SN, Collier L, Pennypacker KR. Temporary focal ischemia in the mouse: technical aspects and patterns of Fluoro-Jade evident neurodegeneration. Brain Res. 2005;1042:29-36. doi: 10.1016/j.brainres.2005.02.021.
37. Bendel O, Alkass K, Bueters T, von Euler M, von Euler G. Reproducible loss of CA1 neurons following carotid artery occlusion combined with halothane-induced hypotension. Brain Res. 2005;1033:135-142. doi: 10.1016/j.brainres.2004.11.033.
38. Falco A, Pennucci R, Brambilla E, de Curtis I. Reduction in parval-bumin-positive interneurons and inhibitory input in the cortex of mice with experimental autoimmune encephalomyelitis. Exp Brain Res. 2014;232:2439-2449. doi: 10.1007/s00221-014-3944-7.
39. Clarke J, Mala H, Windle V, Chernenko G, Corbett D. The effects of repeated rehabilitation "tune-ups" on functional recovery after focal ischemia in rats. Neurorehabil Neural Repair. 2009;23:886-894. doi: 10.1177/1545968309341067.
40. MacLellan CL, Keough MB, Granter-Button S, Chernenko GA, Butt S, Corbett D. A critical threshold of rehabilitation involving brain-derived neurotrophic factor is required for poststroke recovery. Neurorehabil Neural Repair. 2011;25:740-748. doi: 10.1177/1545968311407517.
41. Duncan PW, Lai SM, Keighley J. Defning post-stroke recovery: implications for design and interpretation of drug trials. Neuropharmacology. 2000;39:835-841.
42. Winters C, van Wegen EE, Daffertshofer A, Kwakkel G. Generalizability of the proportional recovery model for the upper extremity after an isch-emic stroke. Neurorehabil Neural Repair. 2014;11:1-9
43. Carmichael ST. Brain excitability in stroke: the yin and yang of stroke progression. Arch Neurol. 2012;69:161-167. doi: 10.1001/archneurol.2011.1175.
44. Centonze D, Rossi S, Tortiglione A, Picconi B, Prosperetti C, De Chiara V, et al. Synaptic plasticity during recovery from permanent occlusion of the middle cerebral artery. Neurobiol Dis. 2007;27:44-53. doi: 10.1016/j.nbd.2007.03.012.
45. Manganotti P, Patuzzo S, Cortese F, Palermo A, Smania N, Fiaschi A. Motor disinhibition in affected and unaffected hemisphere in the early period of recovery after stroke. Clin Neurophysiol. 2002;113:936-943.
46. Laaksonen K, Kirveskari E, Mäkelä JP, Kaste M, Mustanoja S, Nummenmaa L, et al. Effect of afferent input on motor cortex excitability during stroke recovery. Clin Neurophysiol. 2012;123:2429-2436. doi: 10.1016/j.clinph.2012.05.017.
47. Schiene K, Bruehl C, Zilles K, Qü M, Hagemann G, Kraemer M, et al. Neuronal hyperexcitability and reduction of GABAA-receptor expression in the surround of cerebral photothrombosis. J Cereb Blood Flow Metab. 1996;16:906-914. doi: 10.1097/00004647-199609000-00014.
48. Greifzu F, Pielecka-Fortuna J, Kalogeraki E, Krempler K, Favaro PD, Schlüter OM, et al. Environmental enrichment extends ocular dominance plasticity into adulthood and protects from stroke-induced impairments of plasticity. Proc Natl Acad Sci USA. 2014;111:1150-1155. doi: 10.1073/pnas.1313385111.
49. Hensch TK. Critical period plasticity in local cortical circuits. Nat Rev Neurosci. 2005;6:877-888. doi: 10.1038/nrn1787.
50. Hensch TK. Critical period regulation. Annu Rev Neurosci. 2004;27:549-579. doi: 10.1146/annurev.neuro.27.070203.144327.
51. Wahl AS, Omlor W, Rubio JC, Chen JL, Zheng H, Schröter A, et al. Neuronal repair. Asynchronous therapy restores motor control by rewiring of the rat corticospinal tract after stroke. Science. 2014;344:1250-1255. doi: 10.1126/science.1253050.
52. Wahl AS, Schwab ME. Finding an optimal rehabilitation paradigm after stroke: enhancing fber growth and training of the brain at the right moment. Front Hum Neurosci. 2014;8:381. doi: 10.3389/fnhum.2014.00381.
53. Windle V, Corbett D. Fluoxetine and recovery of motor function after focal ischemia in rats. Brain Res. 2005;1044:25-32. doi: 10.1016/j. brainres.2005.02.060.
54. Zhang F, Zhou H, Wilson BC, Shi JS, Hong JS, Gao HM. Fluoxetine protects neurons against microglial activation-mediated neurotoxicity. Parkinsonism Relat Disord. 2012;18(suppl 1):S213-S217. doi: 10.1016/S1353-8020(11)70066-9.
55. Taguchi N, Nakayama S, Tanaka M. Fluoxetine has neuroprotec-tive effects after cardiac arrest and cardiopulmonary resuscitation in mouse. Resuscitation. 2012;83:652-656. doi: 10.1016/j. resuscitation.2011.11.004.
56. Majlessi N, Naghdi N. Impaired spatial learning in the Morris water maze induced by serotonin reuptake inhibitors in rats. Behav Pharmacol. 2002;13:237-242.
57. Valluzzi JA, Chan K. Effects of fuoxetine on hippocampal-dependent and hippocampal-independent learning tasks. Behav Pharmacol. 2007;18:507-513. doi: 10.1097/FBP.0b013e3282ee2a91.
58. Dias BG, Banerjee SB, Duman RS, Vaidya VA. Differential regulation of brain derived neurotrophic factor transcripts by antidepressant treatments in the adult rat brain. Neuropharmacology. 2003;45:553-563.
59. Frick LR, Rapanelli M, Arcos ML, Cremaschi GA, Genaro AM. Oral administration of fuoxetine alters the proliferation/apoptosis balance of lymphoma cells and up-regulates T cell immunity in tumor-bearing mice. Eur J Pharmacol. 2011;659:265-272. doi: 10.1016/j. ejphar.2011.03.037.
60. Schaz U, Föhr KJ, Liebau S, Fulda S, Koelch M, Fegert JM, et al. Dose-dependent modulation of apoptotic processes by fuoxetine in maturing neuronal cells: an in vitro study. World J Biol Psychiatry. 2011;12:89-98. doi: 10.3109/15622975.2010.506927.
61. Lee CS, Kim YJ, Jang ER, Kim W, Myung SC. Fluoxetine induces apoptosis in ovarian carcinoma cell line OVCAR-3 through reactive oxygen species-dependent activation of nuclear factor-kappaB. Basic Clin Pharmacol Toxicol. 2010;106:446-453. doi: 10.1111/j.1742-7843.2009.00509.x.
62. Liu KH, Yang ST, Lin YK, Lin JW, Lee YH, Wang JY, et al. Fluoxetine, an antidepressant, suppresses glioblastoma by evoking AMPAR-mediated calcium-dependent apoptosis. Oncotarget. 2015;6:5088-5101.
63. Núñez MJ, Balboa J, Rodrigo E, Brenlla J, González-Peteiro M, Freire-Garabal M. Effects of fuoxetine on cellular immune response in stressed mice. Neurosci Lett. 2006;396:247-251. doi: 10.1016/j. neulet.2005.11.042.
64. Risedal A, Zeng J, Johansson BB. Early training may exacerbate brain damage after focal brain ischemia in the rat. J Cereb Blood Flow Metab. 1999;19:997-1003. doi: 10.1097/00004647-199909000-00007.
65. Farrell R, Evans S, Corbett D. Environmental enrichment enhances recovery of function but exacerbates ischemic cell death. Neuroscience. 2001;107:585-592.
66. Andrade C, Rao NS. How antidepressant drugs act: A primer on neuro-plasticity as the eventual mediator of antidepressant effcacy. Indian J Psychiatry. 2010;52:378-386. doi: 10.4103/0019-5545.74318.
67. Caiati MD, Cherubini E. Fluoxetine impairs GABAergic signaling in hippocampal slices from neonatal rats. Front Cell Neurosci. 2013;7:63. doi: 10.3389/fncel.2013.00063.
68. Guirado R, Perez-Rando M, Sanchez-Matarredona D, Castren E, Nacher J. Chronic fuoxetine treatment alters the structure, connectivity and plasticity of cortical interneurons. Int J Neuropsychopharmacol. 2014:1-12. doi: 10.1017/S1461145714000406.
69. Mainardi M, Landi S, Berardi N, Maffei L, Pizzorusso T. Reduced responsiveness to long-term monocular deprivation of parvalbumin neurons assessed by c-Fos staining in rat visual cortex. PLoS One. 2009;4:e4342. doi: 10.1371/journal.pone.0004342.
70. Schwaller B. Cytosolic Ca2+ buffers. Cold Spring Harb Perspect Biol. 2010;2:a004051. doi: 10.1101/cshperspect.a004051.
71. Gladstone DJ, Danells CJ, Armesto A, McIlroy WE, Staines WR, Graham SJ, et al; Subacute Therapy with Amphetamine and Rehabilitation for Stroke Study Investigators. Physiotherapy coupled with dextroamphetamine for rehabilitation after hemiparetic stroke: a randomized, double-blind, placebo-controlled trial. Stroke. 2006;37:179-185. doi: 10.1161/01.STR.0000195169.42447.78.
72. Walker-Batson D, Smith P, Curtis S, Unwin H, Greenlee R. Amphetamine paired with physical therapy accelerates motor recovery after stroke. Further evidence. Stroke. 1995;26:2254-2259.
73. Feeney DM, Gonzalez A, Law WA. Amphetamine, haloperidol, and experience interact to affect rate of recovery after motor cortex injury. Science. 1982;217:855-857.
74. Hovda DA, Fenney DM. Amphetamine with experience promotes recovery of locomotor function after unilateral frontal cortex injury in the cat. Brain Res. 1984;298:358-361.
75. Karpova NN, Pickenhagen A, Lindholm J, Tiraboschi E, Kulesskaya N, Agústsdóttir A, et al. Fear erasure in mice requires synergy between antidepressant drugs and extinction training. Science. 2011;334:1731-1734. doi: 10.1126/science.1214592.
76. Khundakar AA, Zetterström TS. Biphasic change in BDNF gene expression following antidepressant drug treatment explained by differential transcript regulation. Brain Res. 2006;1106:12-20. doi: 10.1016/j. brainres.2006.05.063.
77. De Foubert G, Carney SL, Robinson CS, Destexhe EJ, Tomlinson R, Hicks CA, et al. Fluoxetine-induced change in rat brain expression of brain-derived neurotrophic factor varies depending on length of treatment. Neuroscience. 2004;128:597-604. doi: 10.1016/j. neuroscience.2004.06.054.
78. Rogóz Z, Kabzinski M, Sadaj W, Rachwalska P, Gadek-Michalska A. Effect of co-treatment with fuoxetine or mirtazapine and risperidone on the active behaviors and plasma corticosterone concentration in rats subjected to the forced swim test. Pharmacol Rep. 2012;64:1391-1399.
79. Gomes KS, de Carvalho-Netto EF, Monte KC, Acco B, Nogueira PJ, Nunes-de-Souza RL. Contrasting effects of acute and chronic treatment with imipramine and fuoxetine on inhibitory avoidance and escape responses in mice exposed to the elevated T-maze. Brain Res Bull. 2009;78:323-327. doi: 10.1016/j.brainresbull.2008.11.003.
80. Kelly JP, Wrynn AS, Leonard BE. The olfactory bulbectomized rat as a model of depression: an update. Pharmacol Ther. 1997;74:299-316.
81. Uhr M, Steckler T, Yassouridis A, Holsboer F Penetration of ami-triptyline, but not of fuoxetine, into brain is enhanced in mice with blood-brain barrier defciency due to mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology. 2000;22:380-387. doi: 10.1016/S0893-133X(99)00095-0.
82. Bolo NR, Hodé Y, Nédélec JF, Lainé E, Wagner G, Macher JP. Brain pharmacokinetics and tissue distribution in vivo of fuvoxamine and fuoxetine by fuorine magnetic resonance spectros-copy. Neuropsychopharmacology. 2000;23:428-438. doi: 10.1016/S0893-133X(00)00116-0.
83. Henry ME, Moore CM, Kaufman MJ, Michelson D, Schmidt ME, Stoddard E, et al. Brain kinetics of paroxetine and fuoxetine on the third day of placebo substitution: a fuorine MRS study. Am J Psychiatry. 2000;157:1506-1508.
84. Gladstone DJ, Danells CJ, Black SE. The Fugl-Meyer assessment of motor recovery after stroke: a critical review of its measurement properties. Neurorehabil Neural Repair. 2002;16:232-240.